Royal Bank of Canada
AEGR

Royal Bank of Canada’s Aegerion Pharmaceuticals AEGR Stock Holding History

Royal Bank of Canada’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-55,000
Closed -$3.48M – 6396
2013
Q2 		$3.48M Buy
+55,000
New +$2.92M ﹤0.01% 1693

Royal Bank of Canada's AEGR Position: Q4 2016 in Review

Royal Bank of Canada sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 36,200 shares — an estimated $108K sold.

Royal Bank of Canada first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $5.44M in Q3 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • Royal Bank of Canada reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Royal Bank of Canada sold 36,200 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $108K.
  • Royal Bank of Canada first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Royal Bank of Canada's Aegerion Pharmaceuticals position peaked at $5.44M in Q3 2014.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Royal Bank of Canada's 13F filing for Q4 2016, filed 14 Feb 2017.